Brief

New research presented at the American Society of Clinical Oncology meeting suggests that GLP-1 medications, commonly used for diabetes and weight loss, may also reduce the progression of certain cancers. A study analyzing data from over 10,000 patients found that those taking GLP-1 receptor agonists after a cancer diagnosis had a significantly lower risk of their cancer spreading compared to those on other diabetes medications. While these findings offer cautious optimism, researchers emphasize the need for further randomized controlled trials to confirm these effects and understand the underlying mechanisms, which could involve immune system modulation or direct effects on tumor cells. AI

Researchers have developed a new framework called HDMoE to improve multimodal cancer survival prediction. This hierarchical decoupling-fusion mixture-of-experts approach aims to better integrate data from sources like whole slide images and genomic profiles. The framework addresses limitations in existing methods by reducing redundant information before feature decoupling and by modeling fine-grained relationships within and between modalities. AI

Researchers have developed ProtoPathway, a novel multimodal framework designed for predicting cancer survival. This framework integrates whole slide imaging and transcriptomics data by using biologically grounded representations. ProtoPathway employs learnable morphological prototypes for image analysis and a graph neural network for genomic data, enabling cross-modal attention to model the relationship between molecular programs and tissue morphology. The system offers enhanced biological interpretability and reduced computational cost, demonstrating competitive performance on TCGA cancer cohorts. AI